New York Center for Nanomedicine Research
search only ICAHRIS™
Select Language

Management Team

Scottpatrick J. Sellitto
Founding Partner and CEO, NYCNMR

Scottpatrick J. Sellitto

Scottpatrick J. Sellitto is the Chief Executive Officer (CEO) of the New York Center for Nanomedicine Research.
Stanley A. Schwartz
President and Founding Partner, NYCNMR

Stanley A. Schwartz, MD, PhD

Stanley A. Schwartz, MD, PhD, is the President of the New York Center for Nanomedicine Research.
Katherine Cwiklinski
Founding Partner and VP of Operations, NYCNMR

Katherine Cwiklinski

Katherine Cwiklinski is the VP of Operations of the New York Center for Nanomedicine Research.
Pascal Soares
Director of Sales and Marketing, NYCNMR

Pascal Soares

Pascal Soares is Director of Sales and Marketing for the New York Center for Nanomedicine Research.

New York Center for Nanomedicine Research

Core Values

Our Core Value is to increase the health, longevity and quality of life to patients.

The field of 'Nanomedicine' is the science and technology of diagnosing, treating and preventing disease and traumatic injury, of relieving pain and of preserving and improving human health using molecular tools and knowledge of the human body. It is perceived as embracing five main sub-disciplines that, in many ways, are overlapping and underpinned by the following common technical issues:

  • Novel Therapeutics and Drug Delivery Systems
  • Clinical, Regulatory and Toxicological Issues
  • Nanomaterials and Nano-devices
  • Analytical Tools
  • Nano-imaging

The New York Center for Nanomedicine Research is emerging as a critical platform in the New York State Life Science Ecosystem. The mission of the Center is to provide R&D institutions and national and international companies an innovative infrastructure for the discovery of nanoscale therapeutic, clinical, diagnostic and targeting of drug delivery agents and applications.

The aim of the Center is to convene existing research projects from private and public research Institutions with advanced Nanotechnology applications. Clients of the center are Academic / R&D institutions, pharmaceutical, diagnostic and emerging life science companies looking to accelerate new processes from new drug delivery systems.

Capabilities

Our current expertise and production capabilities:

  • Liposomal Delivery and Targeting Systems (Both Natural and Synthetic)
  • Micelle Delivery and Targeting Systems Liposomal and Micelle Release Kinetics Enzymatic or energy based triggering with Notched Vessels for controlled released
  • Intranasal Platform Non-target, targeted, Bioactive or Multimodal Targeting and Delivery of Nanotherapeutics for Peripheral Nervous System Disorders
  • BBB / BNB transport models Nanocarriers for pharmaceutical with controllable properties of water-insoluble drugs, DNA and diagnostic agents to various disease sites
  • Design of multi-functional drug delivery systems with recombinant fusion proteins, liposomes, polymer nanocarriers, monoclonal antibodies and other affinity ligands
  • Nano Cages, Cationic Strings, Graphene, Clay and Polymeric Systems
  • Transfection / Delivery Systems for Drugs and Genetic Materials including Plasmids
  • PDT Compounds and Treatment including 12 licensed IP Technologies
  • Advanced Transdermal Systems
  • Nanoparticle Synthesis Pain, Addiction and Depression Studies Targeting p11 Gene / Protein Expression (NIH) In Vivo Animal Models
  • Pharmacocinetique and Pharmacodynamic models
  • In Vitro 2 and 3 Dim cell culture and Ex Vivo cell culture
  • Next-generation of imaging agents and Multimodal imaging
  • NanoToxicity valuation; Ultra-Fast, Non-toxic Transfecting and Delivery Systems (self-replicating nanodelivery system for neuronal tissues); Non-toxic Quantum dots for Gene Therapy for Cancer, HIV Infections, Asthma, and COPD
  • Gene delivery and Gene knock-down; Gene and protein expression analysis
  • Single Dose Vaccine Systems and Vaccine Development Platforms
  • Transit of Theranostics Across the Blood Brain Barrier